Lisata Buys Marea, Raises $225M, Leaves Holders 2.39%

Lisata Therapeutics closed its Marea Therapeutics acquisition and a $225M private placement, leaving legacy shareholders about 2.39% of the combined company with Phase 2 data due in 2027.